Enzon Pharmaceuticals, Inc. (ENZN)
Stock Price:
$0.162 USD
0.002 (1.25%)
Updated Oct 22, 2020 3:53 PM EDT - Market closed
Key Info
| Market Cap |
7.17M |
| Revenue (ttm) |
61,000 |
| Net Income (ttm) |
-1.07M |
| Shares Out |
44.25M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
$0.12 |
| Dividend Yield |
74.07% |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$0.162 |
| Previous Close |
$0.160 |
| Change ($) |
0.002 |
| Change (%) |
1.25% |
| Day's Open |
0.128 |
| Day's Range |
0.128 - 0.170 |
| Day's Volume |
62,220 |
| 52-Week Range |
0.02 - 0.27 |
More Stats
| Market Cap |
7.17M |
| Enterprise Value |
1.26M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.25M |
| Float |
35.77M |
| EPS (basic) |
-0.03 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
0.18 |
| Dividend |
$0.12 |
| Dividend Yield |
74.07% |
| Earnings Yield |
n/a |
| FCF Yield |
109.47% |
| Payout Ratio |
n/a |
| Shares Short |
157,472 |
| Short Ratio |
1.03 |
| Short % of Float |
0.44% |
| Beta |
0.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
0.91 |
| PS Ratio |
117.53 |
| PB Ratio |
1.28 |
| Revenue |
61,000 |
| Operating Income |
-1.06M |
| Net Income |
-1.07M |
| Free Cash Flow |
7.85M |
| Net Cash |
5.91M |
| Net Cash / Share |
0.13 |
| Gross Margin |
339.34% |
| Operating Margin |
-1,736.07% |
| Profit Margin |
-1,745.90% |
| FCF Margin |
12,865.57% |
| ROA |
-7.19% |
| ROE |
-12.15% |
| ROIC |
153.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
16.0
Current: $0.162
High
16.0
Target: 16.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.21 | 6.92 | 8.38 | 8.38 | 17.46 | 31.17 | 34.49 | 42.60 | 48.07 | 97.87 |
| Revenue Growth | -97.01% | -17.44% | 0.02% | -52.01% | -44% | -9.63% | -19.03% | -11.38% | -50.88% | - |
| Gross Profit | 0.21 | 6.92 | 8.38 | 8.38 | 17.46 | 31.17 | 34.49 | 42.60 | 48.07 | 97.87 |
| Operating Income | -0.97 | 5.86 | 7.01 | 6.64 | 10.80 | 28.79 | 18.16 | -3.97 | -16.46 | -0.58 |
| Net Income | -0.98 | 5.85 | 5.45 | -1.13 | 21.64 | 28.80 | 18.15 | -2.78 | -20.76 | 177 |
| Shares Outstanding | 44.22 | 44.22 | 44.22 | 44.22 | 44.20 | 44.13 | 43.78 | 46.74 | 51.91 | 58.47 |
| Earnings Per Share | -0.02 | 0.13 | 0.12 | -0.03 | 0.49 | 0.65 | 0.38 | -0.06 | -0.40 | 3.03 |
| EPS Growth | - | 8.33% | - | - | -24.62% | 71.05% | - | - | - | - |
| Dividend Per Share | 0.12 | - | 0.15 | 0.15 | 0.85 | - | 3.65 | 2.00 | - | - |
| Dividend Growth | - | - | 0% | -82.35% | - | - | 82.5% | - | - | - |
| Operating Cash Flow | 6.91 | -0.98 | 6.47 | 2.60 | 14.68 | 32.34 | 14.01 | 8.45 | -12.73 | 22.62 |
| Capital Expenditures | - | - | - | - | - | 0.15 | 2.23 | -0.01 | -0.63 | -1.97 |
| Free Cash Flow | 6.91 | -0.98 | 6.47 | 2.60 | 14.68 | 32.49 | 16.24 | 8.44 | -13.35 | 20.65 |
| Cash & Equivalents | 5.45 | 6.50 | 7.48 | 7.64 | 11.67 | 34.56 | 6.52 | 197 | 323 | 460 |
| Total Debt | - | - | - | - | - | - | - | 116 | 129 | 134 |
| Net Cash / Debt | 5.45 | 6.50 | 7.48 | 7.64 | 11.67 | 34.56 | 6.52 | 80.89 | 194 | 326 |
| Assets | 6.48 | 15.51 | 9.51 | 11.27 | 22.89 | 35.04 | 7.12 | 200 | 343 | 489 |
| Liabilities | 0.42 | 0.52 | 0.37 | 0.94 | 4.80 | 5.44 | 1.87 | 122 | 146 | 157 |
| Book Value | 6.06 | 14.99 | 9.14 | 10.33 | 18.09 | 29.60 | 5.26 | 77.47 | 197 | 332 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Enzon Pharmaceuticals, Inc. |
| Country |
United States |
| CEO |
Andrew D. Rackear |
Stock Information
| Ticker Symbol |
ENZN |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: ENZN |
| IPO Date |
February 15, 1984 |
Description
Enzon Pharmaceuticals is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.